|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- The Rising Mountain of Debt May Be the Next Crisis
- SEC May Reinstate Rules for Short-Selling Stocks
- Latvian Banker Taking Souls as Collateral
- A Goldman Trading Scandal?
- Cuddle Parties Heat Up
- Alaska Governor Sarah Palin Will Resign
- The Worst Expected 2010 State Budget Gaps
- NY City Apartment Sales Down More Than 50%
- A Goldman Trading Scandal?
- Top Videos: From the Black Swan to the Bond King

- Obama Plan Would Trim Back Financial Powerhouses
- Biden: 'We Misread How Bad The Economy Was'
- FedEx Sees Signs of a Turnaround: Report
- Property Tax Appeals Take Toll on Governments
- Chrysler Names Remaining Directors to New Board
- Car Dealer Determined To Fight Chrysler Over Franchise
- 'Ice Age' Heats Up Worldwide Box Office
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
Shares of Amgen surged Monday after the company reported positive trial results for its osteoporosis drug candidate denosumab—which one analyst terms "a future blockbuster."
After the market closed Friday, Amgen reported late-stage clinical trial results that showed denosumab reduced the incidence of fractured vertebrae in post-menopausal women. Serious side effects were similar to a placebo injection—which, analysts said, will help eliminate concerns about the drug's safety.
The most common side effects were back and joint pain, hypertension and inflamed nasal passages.
Amgen [AMGN
Loading...
()
] stock climbed more than $7, or 13 percent, to almost $61 after the opening bell.
Rodman & Renshaw analyst Michael King said the results provide clearer data about the benefits and risks of denosumab. Because the side effects were similar to a placebo, he said, the drug's status as "a future blockbuster" is secure.
King raised his rating on Amgen stock to "market outperform" from "market perform," with a price target of $80 per share.
Jefferies analyst Adam Walsh also upgraded the Thousand Oaks, Calif., company to "buy" from "hold" and raised his target to $71 from $47. He estimated peak sales of $2 billion to $3 billion for denosumab—while May-Kin Ho of Goldman Sachs said sales could reach $5 billion if the drug is also approved to treat hormone-induced bone loss in cancer.
Ho said Amgen should report data from a cancer trial in late 2008 or early 2009, and she expects the drug to reach the market in 2010.
She raised her price target to $74 per share from $63.
Amgen is scheduled to release second-quarter results after the bell. Analysts on average expect earnings of $1.02 cents a share, on revenue of $3.58 billion, according to analyst estimates.









